Hologic, Inc. (NASDAQ:HOLX – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are presently covering the stock, MarketBeat Ratings reports. Five investment analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month price target among analysts that have covered the stock in the last year is $85.73.
Several equities research analysts have recently commented on HOLX shares. Stephens started coverage on shares of Hologic in a research report on Thursday. They set an “overweight” rating and a $87.00 target price for the company. Needham & Company LLC reissued a “buy” rating and set a $90.00 price objective on shares of Hologic in a report on Friday, May 3rd. Citigroup upgraded Hologic from a “neutral” rating to a “buy” rating and raised their target price for the company from $80.00 to $95.00 in a report on Wednesday, April 3rd. Evercore ISI upped their price target on Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a report on Thursday, April 4th. Finally, JPMorgan Chase & Co. increased their price target on Hologic from $85.00 to $91.00 and gave the company an “overweight” rating in a research report on Friday, May 3rd.
Read Our Latest Analysis on Hologic
Institutional Inflows and Outflows
Hologic Stock Performance
Shares of Hologic stock opened at $74.25 on Friday. The business has a 50-day simple moving average of $74.32 and a 200 day simple moving average of $74.30. Hologic has a one year low of $64.02 and a one year high of $82.45. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.97 and a quick ratio of 3.29. The firm has a market capitalization of $17.33 billion, a price-to-earnings ratio of 37.88, a PEG ratio of 2.47 and a beta of 1.00.
Hologic (NASDAQ:HOLX – Get Free Report) last released its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $0.98 by $0.05. Hologic had a return on equity of 18.91% and a net margin of 11.78%. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1 billion. During the same quarter in the previous year, the company posted $1.06 earnings per share. The company’s quarterly revenue was down .8% on a year-over-year basis. On average, research analysts anticipate that Hologic will post 4.08 earnings per share for the current fiscal year.
About Hologic
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
See Also
- Five stocks we like better than Hologic
- 3 Warren Buffett Stocks to Buy Now
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- MarketBeat Week in Review – 6/24 – 6/28
- What is the FTSE 100 index?
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.